Laboratory of Cancer Progression Biology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
Department of Thoracic Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
Cell Physiol Biochem. 2021 Mar 10;55(S2):29-48. doi: 10.33594/000000340.
Despite advances in diagnostics and therapy of non-small cell lung cancer (NSCLC), the problem of prognosis and prevention of tumor progression is still highly important. Even if NSCLC is diagnosed in the early stages, almost a quarter of patients develop relapse; most of them die from recurrent disease. A large number of different markers have been proposed to predict the risk of NSCLC progression; however, none of them are used in clinical practice. It is obvious that this situation is related to the economic and methodological complexity of the proposed markers and/or their insufficient efficiency due to a lack of effective study models and tumor heterogeneity. Another reason may be that potential markers are developed for NSCLC progression in general, which is represented by at least four pathogenetically-distinct processes: synchronous lymph node metastasis, local, regional, and distant recurrence. In this review, we summarize data from published literature on clinicopathological, genetic, and molecular factors associated with different types of NSCLC progression and emphasize challenges and approaches to developing prognostic factors. In conclusion, we highlight the importance of further studies to reveal molecular mechanisms of NSCLC progression and the need for differential analysis of markers of local, regional, and distant recurrences for disease prognosis.
尽管在非小细胞肺癌(NSCLC)的诊断和治疗方面取得了进展,但预测肿瘤进展和预防肿瘤进展的问题仍然非常重要。即使在早期诊断出 NSCLC,仍有近四分之一的患者会复发;其中大多数死于复发性疾病。已经提出了许多不同的标志物来预测 NSCLC 进展的风险;然而,由于缺乏有效的研究模型和肿瘤异质性,它们都没有在临床实践中使用。很明显,这种情况与所提出的标志物的经济和方法学复杂性以及由于缺乏有效性而导致的效率低下有关研究模型。另一个原因可能是潜在的标志物通常是针对 NSCLC 的一般进展而开发的,这至少代表了四种发病机制不同的过程:同步淋巴结转移、局部、区域和远处复发。在这篇综述中,我们总结了已发表文献中与不同类型 NSCLC 进展相关的临床病理、遗传和分子因素的数据,并强调了开发预后因素所面临的挑战和方法。总之,我们强调了进一步研究揭示 NSCLC 进展的分子机制以及对局部、区域和远处复发的标志物进行差异分析以预测疾病预后的重要性。